Sandoz announced that it has signed an agreement to acquire Coherus Biosciences’ Cimerli®, biosimilar to Genentech’s Lucentis® (ranibizumab), for US$170M. The deal includes the biologics license application (BLA), product inventory, ophthalmology sales and field reimbursement talent and access to proprietary commercial software. Closing is anticipated in the first half of 2024, subject to standard conditions and approvals.
Coherus announced its sales of Cimerli® surpassed 100,000 doses in its first year in the US following launch in October 2022.